Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

por Rubbert-Roth, Andrea, Tak, Paul P., Zerbini, Cristiano, Tremblay, Jean-Luc, Carreño, Luis, Armstrong, Gillian, Collinson, Neil, Shaw, Tim M.
Publicado 2010

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

por Charles-Schoeman, Christina, Burmester, Gerd, Nash, Peter, Zerbini, Cristiano A F, Soma, Koshika, Kwok, Kenneth, Hendrikx, Thijs, Bananis, Eustratios, Fleischmann, Roy
Publicado 2016

Maintenance of low disease activity and remission with etanercept–disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Lati...

por Zerbini, Cristiano A.F., Abud-Mendoza, Carlos, Mendez-Patarroyo, Paul, De Angelo Andrade, Mauricio, Pedersen, Ron, Vlahos, Bonnie, Borlenghi, Cecilia Elena
Publicado 2018

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil

por Zerbini, Cristiano A.F., Ribeiro dos Santos, Rodrigo, Jose Nunes, Maria, Soni, Jyoti, Li, Ping, Jain, Varsha K., Ofori-Anyinam, Opokua
Publicado 2016

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

por Stohl, William, Gomez-Reino, Juan, Olech, Ewa, Dudler, Jean, Fleischmann, Roy M, Zerbini, Cristiano A F, Ashrafzadeh, Ali, Grzeschik, Susanna, Bieraugel, Rebecca, Green, Jennifer, Francom, Steven, Dummer, Wolfgang
Publicado 2012

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

por Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Publicado 2014

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

por Lomonte, Andrea B.V., Radominski, Sebastião C., Marcolino, Flora M.D., Brenol, Claiton V., Zerbini, Cristiano A.F., García, Erika G., Akylbekova, Ermeg L., Rojo, Ricardo, de Leon, Dario Ponce
Publicado 2018

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

por Cohen, Stanley B, van Vollenhoven, Ronald F, Winthrop, Kevin L, Zerbini, Cristiano A F, Tanaka, Yoshiya, Bessette, Louis, Zhang, Ying, Khan, Nasser, Hendrickson, Barbara, Enejosa, Jeffrey V, Burmester, Gerd R
Publicado 2021

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

por Fleischmann, Roy M, Blanco, Ricardo, Hall, Stephen, Thomson, Glen T D, Van den Bosch, Filip E, Zerbini, Cristiano, Bessette, Louis, Enejosa, Jeffrey, Li, Yihan, Song, Yanna, DeMasi, Ryan, Song, In-Ho
Publicado 2021

Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

por Taylor, Peter C, Betteridge, Neil, Brown, T Michelle, Woolcott, John, Kivitz, Alan J, Zerbini, Cristiano, Whalley, Diane, Olayinka-Amao, Oyebimpe, Chen, Connie, Dahl, Palle, Ponce de Leon, Dario, Gruben, David, Fallon, Lara
Publicado 2020

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBE...

por Silva, Barbara C., Madeira, Miguel, d’Alva, Catarina Brasil, Maeda, Sergio Setsuo, de Holanda, Narriane Chaves Pereira, Ohe, Monique Nakayama, Szejnfeld, Vera, Zerbini, Cristiano A. F., de Paula, Francisco José Albuquerque, Bandeira, Francisco
Publicado 2022

Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys

por Gibofsky, Allan, Galloway, James, Kekow, Joern, Zerbini, Cristiano, de la Vega, Maria, Lee, Gavin, Lee, Eun Young, Codreanu, Catalin, Koehn, Cheryl, Steinberg, Kathy, Bananis, Eustratios, de Leon, Dario Ponce, Maniccia, Anna, Dikranian, Ara
Publicado 2018

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study...

por van der Heijde, Désirée, Strand, Vibeke, Tanaka, Yoshiya, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano A. F., Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Gruben, David, Wallenstein, Gene, Connell, Carol A., Fleischmann, Roy
Publicado 2019

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postm...

por Brown, Jacques P., Engelke, Klaus, Keaveny, Tony M., Chines, Arkadi, Chapurlat, Roland, Foldes, A. Joseph, Nogues, Xavier, Civitelli, Roberto, De Villiers, Tobias, Massari, Fabio, Zerbini, Cristiano A.F., Wang, Zhenxun, Oates, Mary K., Recknor, Christopher, Libanati, Cesar
Publicado 2021

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

por Fleischmann, Roy, Schiff, Michael, van der Heijde, Désirée, Ramos‐Remus, Cesar, Spindler, Alberto, Stanislav, Marina, Zerbini, Cristiano A. F., Gurbuz, Sirel, Dickson, Christina, de Bono, Stephanie, Schlichting, Douglas, Beattie, Scott, Kuo, Wen‐Ling, Rooney, Terence, Macias, William, Takeuchi, Tsutomu
Publicado 2017

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

por Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L., DeLozier, Amy M., Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A. F.
Publicado 2017

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

por Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
Publicado 2016

Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumato...

por Yang, Yue, Xu, Jianhua, Xu, Jian, Li, Xingfu, Hu, Jiankang, Li, Xiangpei, Zhang, Xiao, He, Dongyi, Bao, Chunde, Li, Zhijun, Wang, Guochun, Zerbini, Cristiano A. F., Spindler, Alberto J., Kannowski, Carol L., Wu, Hanjun, Ji, Fei, Zhan, Lujing, Liu, Mengru, Li, Zhanguo
Publicado 2021

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

por Yang, Yue, Li, Xing-Fu, Zhang, Xiao, Bao, Chun-De, Hu, Jian-Kang, Xu, Jian-Hua, Li, Xiang-Pei, Xu, Jian, He, Dong-Yi, Li, Zhi-Jun, Wang, Guo-Chun, Wu, Han-Jun, Ji, Fei, Zhan, Lu-Jing, Zerbini, Cristiano A. F., Li, Zhan-Guo
Publicado 2020

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

por Austin, Matthew, Yang, Yu-Ching, Vittinghoff, Eric, Adami, Silvano, Boonen, Steven, Bauer, Douglas C, Bianchi, Gerolamo, Bolognese, Michael A, Christiansen, Claus, Eastell, Richard, Grauer, Andreas, Hawkins, Federico, Kendler, David L, Oliveri, Beatriz, McClung, Michael R, Reid, Ian R, Siris, Ethel S, Zanchetta, Jose, Zerbini, Cristiano AF, Libanati, Cesar, Cummings, Steven R
Publicado 2012